Drug intelligence / Profile preview

HLB1-015

Development stage: Preclinical
Lead developer: Huons Global
Modality: Recombinant Proteins and Enzymes, Peptides

Overview

HLB1-015 is a preclinical-stage therapeutic candidate developed for the treatment of obesity. It is a recombinant polypeptide that acts as a long-acting dual agonist of the glucagon-like peptide 1 receptor (GLP-1R) and glucagon-like peptide 2 receptor (GLP-2R). By mimicking the body's natural incretin hormones, HLB1-015 aims to enhance weight loss through mechanisms such as reducing appetite, slowing gastric emptying, and promoting satiety. The dual activation of GLP-1 and GLP-2 receptors is intended to provide sustained weight management with minimal side effects[1][8].

Other names: Long-acting GLP-1R/-2R dual agonist (Huons)

Targets

GLP2R (Glucagon-like peptide 2 receptor)GLP1R (GLP-1R)

Beyond the preview

Go deeper on HLB1-015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLB1-015.

Explore the full profile